BTIG Maintains Buy on DermTech, Lowers Price Target to $5
Portfolio Pulse from jenniferd'souza@benzinga.com
BTIG analyst Mark Massaro has maintained a 'Buy' rating on DermTech (NASDAQ:DMTK) but lowered the price target from $6 to $5.
August 07, 2023 | 3:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
DermTech's price target has been lowered from $6 to $5 by BTIG, though the 'Buy' rating is maintained.
The news directly pertains to DermTech (DMTK) as BTIG analyst Mark Massaro has lowered the price target for the company. However, the 'Buy' rating is maintained which indicates a positive outlook for the company. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100